Altan Pharma Announces Licensing Agreement for Generic of Antifungal Agent Caspofungin

March 4, 2016 9:00 am

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that it has signed a licensing agreement to commercialise a generic version of caspofungin. The agreement covers the territories of Germany, France, Italy, Spain, the United Kingdom, Belgium, Portugal, Poland and Latin America.

Chairman and Chief Executive Officer of Altan Pharma, Guillermo Herrera stated: “Licensing the rights to generic caspofungin reflects a significant step forward for Altan as we continue to build a strong portfolio of injectable drugs which we can bring to the European and other markets. Altan are committed to building a deep and diverse pipeline through ongoing internal development, in-licensing and further acquisitions.”

According to IMS, the market for caspofungin in the European countries covered by the agreement was approximately €260 million 2015.


Caspofungin is an antifungal medicine indicated for the:

  • Treatment of invasive candidiasis in adult or pediatric patients;
  • Treatment of invasive aspergillosis in adult or pediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or Iitraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;
  • Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropenic adult or pediatric patients.

Please see the package insert for indications, complete side effect profile and prescribing information.

Altan Media Relations
Mark Gorman
Tel: +353 (1) 908 1280